biostudies-literatureUnknown12(3)Bartolomeo RQuality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector products: GAd-209 and MVA-209. These consist of a mix of four Adeno (Great Ape Adenovirus; GAd) and four Modified Vaccinia Ankara (MVA) vectors respectively, each containing a different transgene encoding a synthetic polypeptide composed of antigenic peptide fragments joined one after the other. The potency assay employs quantitative Reverse Transcription PCR (RT-Q-PCR) to quantitatively measure the transcripts from the four transgenes encoded by each product in in vitro infected cells, enabling simuVaccines325https://www.ebi.ac.uk/biostudies/studies/S-EPMC10975996biostudies-literatureDevelopment of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.PMC10975996Troise FRuzza VGarzia IVitale RCotugno GRomano GSdruscia GBignone VAllocca SSiani LLanzaro FScarselli EPetrone AMD'Alise AMMerone RColloca SLeoni GBartolomeo RfalseDevelopment of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector products: GAd-209 and MVA-209. These consist of a mix of four Adeno (Great Ape Adenovirus; GAd) and four Modified Vaccinia Ankara (MVA) vectors respectively, each containing a different transgene encoding a synthetic polypeptide composed of antigenic peptide fragments joined one after the other. The potency assay employs quantitative Reverse Transcription PCR (RT-Q-PCR) to quantitatively measure the transcripts from the four transgenes encoded by each product in in vitro infected cells, enabling simu2024-01-01T00:00:00Z2024 Mar2026-07-09T10:54:53.169Z2025-04-04T19:11:13.994ZS-EPMC109759963854395910.3390/vaccines12030325